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Disease modeling using induced 
pluripotent stem cells (iPSCs) and human 
embryonic stem cells (hESCs) promises 
to reveal underlying pathophysiology, 
especially for genetic diseases that manifest 
pathologic tissue development, or in cases 
where disease tissues are largely destroyed 
by disease at the time of diagnosis. 
Shwachman–Diamond syndrome (SDS), 
a rare pediatric disease marked by 
neutropenia (bone marrow failure) and 
exocrine pancreatic insufficiency, is one 
such condition. Given its low prevalence 
and the need for invasive procedures in 
affected children to acquire pancreatic 
or bone marrow samples, obtaining 
primary diseased tissues is challenging. 
The availability of iPSCs from affected 
patients, however, affords the opportunity 
to revisit hematopoietic and pancreatic 
tissue development in vitro, with scientists 
holding a ringside seat.
SDS is associated with mutations 
in the Shwachman–Bodian–Diamond 
syndrome (SBDS) gene,1 which encodes 
a protein involved in 60S ribosomal 
subunit maturation2; however, why 
a general ribosomal assembly defect 
should manifest as pathology within the 
pancreatic and hematopoietic lineages 
has remained a mystery. Our laboratory 
recently addressed this question through 
disease modeling of SDS with iPSCs 
and hESCs.3 We reprogrammed iPSCs 
from patients with SDS4,5 as well as 
knocked down the SBDS gene using 
short hairpin inhibitory RNAs.3 We 
then rescued these cells with lentiviral 
vectors carrying either normal SBDS or 
an empty vector to generate appropriately 
matched gene-corrected control lines. We 
found that, once differentiated into target 
tissues, iPSCs/hESCs with SDS protein 
deficiency but not gene-corrected control 
cell lines recapitulated the pancreatic, 
hematopoietic, and ribosomal defects 
observed in patients.3 These findings 
demonstrated that our iPSC/hESC 
differentiated tissues appropriately model 
SDS in vitro.
By analysis of cellular morphology and 
various biochemical features of the cell 
cultures, we found that both pancreatic 
and hematopoietic cells differentiated 
from SBDS-deficient iPSC/hESC cell 
lines expressed larger and greater numbers 
of pancreatic zymogenic and myeloid 
azurophilic granules, higher protease 
levels, and more prominent regions of 
cell death compared with gene-corrected 
controls. Interestingly, incubation with 
aprotinin or cocktails of anti-proteolytic 
compounds during differentiation 
increased cell survival and restored normal 
morphology in cultures,3 leading us to 
hypothesize that increased protease levels 
predispose these highly granule-laden 
cells to auto-digestion, thereby providing 
a common pathogenic mechanism to 
explain the defects in pancreas and bone 
marrow cells from SDS patients. We 
speculate that, when stimulated, these 
abnormal granules release activated 
proteases either intracellularly or in the 
proximal extracellular space, resulting 
in auto-digestion of the cells and tissue 
destruction. Consequently, cell death of 
pancreatic acinar cells or early myeloid 
cells, both of which have naturally high 
numbers of granules, results in functional 
tissue deficiency.
Anti-proteolytic compounds may 
offer a novel therapeutic option for 
patients with SDS, perhaps for patients 
experiencing acute exacerbations of 
neutropenia and infection. While the 
previously FDA-approved compound 
aprotinin (Trasylol™) was withdrawn 
from the market, newer anti-proteolytic 
compounds have been FDA-approved, 
such as the kallikrein inhibitor ecallantide 
(Kalbitor™), or are under development, 
such as the neutrophil elastase inhibitor 
depelestat, making them attractive options 
for investigation. We postulate that 
exocrine pancreatic cells differentiated 
from SDS patient-derived iPSC will 
provide a platform for screening the 
efficacy of anti-proteolytic compounds 
in this disease. Any compound successful 
in a broad iPSC-based drug screen could 
then be introduced into an animal model, 
such as a conditional knockout mouse 
that replicates the phenotype of SDS,6 
and, if promising, translated into a pilot 
clinical trial. A parallel approach for 
identifying therapeutic compounds will 
be especially helpful in the hematopoietic 
compartment, as infection secondary to 
neutropenia is a major cause of mortality 
in patients with SDS.
Using stem cell-derived tissues from 
SDS patients will also allow investigations 
into ribosome biology. A fully functioning 
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ribosome requires a complex formed 
between the 40S subunit, the 60S subunit, 
and mRNA, assisted by numerous 
accessory proteins. SBDS participates 
in the release of an accessory protein, 
eukaryotic initiation factor 6 (eIF6) from 
the pre-60S subunit, thereby allowing its 
binding with the 40S/mRNA complex. 
Therefore, iPSC cultures from patients 
with SDS model a defect in a 60S subunit 
maturation. Many other diseases occur 
due to other faulty steps in ribosomal 
biogenesis. For example, Diamond 
Blackfan anemia (DBA) can result from 
defects in 40S subunit maturation. A 
recently reported iPSC model of DBA7 
along with our iPSC/hESC model of 
SDS may prove valuable in teasing out 
the mechanisms underlying ribosomal 
maturation, in describing the pathogenesis 
of when maturation fails, and in testing 
compounds or stimuli that can alter or 
correct maturation defects. Our laboratory 
has likewise recently generated iPSC from 
Pearson marrow pancreas syndrome, a 
mitochondrial disorder, to investigate 
basic mitochondrial biology, providing an 
example of using stem cell technologies 
to interrogate organelle function and 
involvement in disease.8
iPSCs and hESCs demonstrate 
significant potential in revealing the 
pathogenesis of human disease and for 
testing pharmaceutical therapies. We 
anticipate many more insights to emerge 
from this “disease-in-a-dish” approach.
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